Brief: Xvivo Gains Regulatory Approval In China For Perfadex Plus
Feb 2 (Reuters) - XVIVO PERFUSION AB:
* XVIVO GAINS REGULATORY APPROVAL IN CHINA FOR PERFADEX® PLUS
Source text for Eikon: ID:nMFN974KSK
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength